Support product quality and regulatory readiness with release and stability methods such as CE-SDS, SE-UPLC, icIEF, HCP and sterility testing.

FDA's May 2026 guidance brings science- and risk-based CMC approaches into one resource that may help cell and gene therapy sponsors prepare a BLA.